Roze bril schreef op 5 maart 2020 17:02:
Het is aan Acacia om te beslissen of ze Cosmo volledig zullen uitbetalen in liquide of deels in liquide en deels in aandelen. Maar waar ze dan die 30 miljoen vandaan gaan halen is mij niet duidelijk, want zoveel cash-voorraad hebben ze niet.
Under the principal terms of the in-license agreement, Cosmo will be eligible for:
- an upfront payment of €10 million from Acacia Pharma to be satisfied through the issue of 4,646,841 new ordinary shares of 2p in Acacia Pharma at €2.152 per share, being the 15-day volume weighted average share price up to 8 January 2020
- a €30 million payment from Acacia Pharma upon US approval of ByFavo, consisting of €15 million payable in cash and €15 million payable in cash or new ordinary shares at Acacia Pharma’s option
- a €5 million payment upon first commercial sale of ByFavo in the US payable in cash or new ordinary shares at Acacia Pharma’s option
- sales-related milestones of up to €105 million upon achieving pre-specified annual sales targets, and
- tiered double-digit royalties on US sales.